Nerelimomab
Based on 1 publication(s) in Google Scholar
Nerelimomab (BAYX1351) is an anti-TNF-α antibody. Nerelimomab can be used for research of sepsis.
For research use only. We do not sell to patients.
- CAS No.: 162774-06-3
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Publications Citing Use of MedChemExpress (MCE) Nerelimomab
More
Biological Activity
Human IgG1 kappa
Human
TNF
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Baboon model of recurrent bacteremia (Challenged with E.coli)[1]
-
Dosage:7.5 mg/kg
-
Administration:i.v. infusion
-
Result:Improved organ function and attenuated cytokine and plasminogen activator inhibitor release.
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
IgG1-nd
ELISA, FACS, Functional assay
Chemical Information
-
CAS No. 162774-06-3
-
SMILES
[Nerelimomab]
-
Synonyms
BAYX1351
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Publications (1)
-
Journal Impact Factor
-
Most Recent
-
Pharmaceuticals (Basel)
Nerelimomab Alleviates Capsaicin-Induced Acute Lung Injury by Inhibiting TNF Signaling and Apoptosis. [Abstract]2024 Dec 15;17(12):1694. PMID: 39770536
Purity & Documentation
References
[1]. Schlag G, et al. Anti-tumor necrosis factor antibody treatment of recurrent bacteremia in a baboon model. Shock. 1994 Jul;2(1):10-8; discussion 19-22. [Content Brief]
[2]. Cohen J, et al. INTERSEPT: an international, multicenter, placebo-controlled trial of monoclonal antibody to human tumor necrosis factor-alpha in patients with sepsis. International Sepsis Trial Study Group. Crit Care Med. 1996 Sep;24(9):1431-40. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Powered by Bioz